Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced three presentations of updated clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2019, to be held March 29-April...
Phase Ib First-in-Human study in ß -Thalassemia and MDS patients, with the first patient expected to enter the clinic in Q3 2019 Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA...
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present next week at the Influenza Vaccines for the Worldconference in Edinburgh, Scotland, UK. Joshua Phillipson, BiondVax’s Head...
Blinded, randomized, placebo-controlled, 40-week extension trial, TRCA-301E, met its primary and all secondary endpoints, supporting the long-term safety and efficacy profile of TRC101 Patients treated with TRC101 showed a significant reduction in all-cause mortality...
LUND, Sweden, March 26, 2019 /PRNewswire/ — Hansa Biopharma AB(NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it received Clinical Trial Application and Ethics Committee approvals...
Email
Text